COMPETE

Radioligand therapy significantly prolongs progression-free survival in patients with the most common type of neuroendocrine tumors compared to standard of care

Published in The Lancet, results of the phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly…

Radioligand therapy demonstrates improved clinical benefit in patients with gastroenteropancreatic neuroendocrine tumors vs. molecular targeted therapy

Initial results of the COMPETE phase 3 clinical trial⁠—the first study to compare targeted radioligand therapy with molecular targeted therapy…